The review, led by Julia Yescas and colleagues at Northwestern University Feinberg School of Medicine, together with collaborators at Yale, Case Western Reserve, and MD Anderson Cancer Center, examines how aggressive cutaneous T-cell lymphomas become addicted to dysregulated kinase signaling and how that addiction becomes both a therapeutic vulnerability and an escape route. The authors argue that understanding the molecular architecture of resistance is essential for designing next-generation inhibitors and rational combination strategies that could finally deliver durable remissions in these devastating diseases.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma, first recognized as a distinct entity in 1999, is characterized by epidermotropic CD8-positive cytotoxic T cells expressing granzyme B, perforin, and TIA-1. Despite its rarity, the disease carries a median overall survival of just 32 months and a five-year survival of only 31 percent. Recent high-throughput genomic studies have revealed that this lymphoma harbors recurrent and targetable kinase fusions at striking frequency. In one study, fusion genes involving JAK2 were detected in three of twelve patients, while another reported kinase gene fusions in six of six samples, with five harboring a JAK2 fusion and one carrying a novel ABL1 fusion. A separate report described a fusion joining SATB1 to FGFR1, a receptor tyrosine kinase for fibroblast growth factors. In all cases, the tyrosine kinase domains are conserved at the C-terminus and fused to a diverse set of partner genes including STAT3, KHDRBS1, PICALM, CAPRIN1, PCM1, and TFG. The biological basis for the recurrent involvement of JAK2, rather than the JAK1 and JAK3 family members typically utilized by CD8-positive T cells, remains unknown, though the authors speculate it may reflect lineage infidelity, with transformed cells deviating from canonical cytokine signaling to exploit JAK2-mediated proliferative pathways.

Primary cutaneous gamma delta T-cell lymphoma presents a different genomic landscape. This rare and highly aggressive subset, with a median overall survival of approximately 31 months and a five-year disease-specific survival of only 19.9 percent, is characterized by marked genomic instability, with a median of 166.5 somatic copy number variants per sample. Rather than kinase fusions, PCGDTL harbors recurrent point mutations in key oncogenic signaling pathways, including the MAPK pathway (KRAS, NRAS, MAPK1), the MYC pathway (MYC, MYCN, FBXW7), and the JAK/STAT pathway (STAT3, STAT5B, JAK3, SOCS1). Among these, KRAS mutations were most common, while approximately 21 percent of samples carried JAK/STAT point mutations. Notably, clinical and histopathologic features correlate with TCR delta-chain usage—epidermal and dermal cases typically express TRVδ1, while subcutaneous cases express TRδV2—yet next-generation sequencing has not identified major mutational differences between these subsets.

The clinical experience with targeted inhibitors in both subtypes tells a consistent story of initial sensitivity followed by adaptive escape. In the first reported clinical use of a tyrosine kinase inhibitor in PCAETL, a patient harboring the SATB1-FGFR1 fusion was treated with the FGFR inhibitor pemigatinib. The response was remarkable: approximately 90 percent regression of ulcerated lesions within two weeks, with partial remission maintained for around four months. However, adverse events including hyperphosphatemia, nail changes, and ocular irritation necessitated a dose reduction. The patient’s lesions relapsed within one month, and sequencing revealed secondary point mutations within the FGFR1 kinase domain. The patient expired two months later. In PCGDTL, a patient with SOCS1 loss treated with the JAK1/2 inhibitor ruxolitinib achieved near-complete regression after four weeks, but disease progression occurred after eight weeks, accompanied by newly acquired lesions. Sequencing of the relapse sample revealed a STAT5B p.N642H mutation, a well-characterized gain-of-function driver associated with T-cell neoplasms and drug-resistant leukemias. Another PCGDTL patient harboring a JAK3 p.A573V mutation was enrolled in a phase II trial of the dual SYK/JAK inhibitor cerdulatinib, achieving an 86 percent reduction in skin disease burden after seven weeks. But therapy was discontinued due to grade 3 adverse events, and shortly after, relapse occurred with sequencing revealing acquired JAK3 p.M511I, JAK1 p.L783F, and JAK1 p.T901A mutations in circulating tumor cells.

The structural basis of these resistance mutations reveals elegant molecular logic. In the FGFR1 case, two secondary mutations were detected following pemigatinib treatment: E462V in the juxtamembrane region and V561L in the kinase domain. The E462V substitution, despite its location in a critical signaling hub, did not confer resistance—structural modeling showed no clashes or modulation of the drug-binding state. In contrast, V561L represents a canonical gatekeeper mutation that sterically impedes inhibitor binding and enhances ATP affinity, thereby reducing drug potency. Structural modeling of the analogous V561M substitution revealed that replacement with a bulky methionine side chain induces steric clashes within the inhibitor-binding pocket, accounting for observed resistance. This mutation has been previously described in FGFR1-driven myeloproliferative neoplasms, where it confers broad resistance to multiple FGFR inhibitors.

In the JAK pathway, the resistance architecture is equally instructive. The STAT5B p.N642H mutation occurs in the Src homology 2 domain and stabilizes STAT5B dimers, increases phosphorylation, and renders the protein constitutively active. Structural studies indicate that this substitution alters the hydrogen-bonding network within the phosphotyrosine pocket, favoring inter-protein interactions in the STAT5B dimer. The JAK3 mutations follow a different logic: M511 lies within the SH2-pseudokinase linker, which typically interacts with the kinase domain active site, and the M511I substitution destabilizes this linker, promoting kinase domain activation. A573 is located within the alphaC helix of the pseudokinase domain, a structural element that toggles between active and inactive conformations. Through structural modeling with cerdulatinib, the combination of M511I and A573V causes steric hindrance, suggesting these variants confer resistance through inter- or intramolecular interaction alterations. Remarkably, the JAK1 p.L783F mutation, which also causes steric hindrance with cerdulatinib, occurs in a different JAK family member than JAK3, raising important questions about how cross-kinase cooperation contributes to drug resistance. The combined presence of JAK3 p.A573V and JAK1 p.L783F conferred greater resistance to cerdulatinib compared to single mutants, indicating cooperative resistance across paralogous kinases.

Toxicity emerges as an indirect but powerful facilitator of resistance. Pemigatinib’s most common adverse events include hyperphosphatemia, nail toxicity, alopecia, diarrhea, anemia, dry eyes, and serous retinal detachment—manifestations that reflect the broad physiological role of FGFR signaling in the corneal epithelium, photoreceptors, iris, and hair follicles. Ruxolitinib, evaluated in a phase II trial of 53 patients with CTCL, produced anemia in 15 patients, diarrhea in 7, thrombocytopenia in 9, and neutropenia in 10, reflecting the critical role of JAK2 signaling in erythropoietin and thrombopoietin receptor function. Cerdulatinib, targeting both SYK and JAK families, produced frequent grade 3 or higher adverse events in a phase II trial of relapsed or refractory peripheral T-cell lymphoma and CTCL, including increased lipase in 29.2 percent, increased amylase in 43.1 percent, diarrhea in 43.1 percent, and anemia in 32.3 percent. Serious adverse events occurred in 64.6 percent of patients, and tragically, two deaths not related to disease progression were attributed to the drug. When dose reductions or discontinuations become necessary, resistant subclones may gain a selective advantage under reduced drug exposure.

The review argues that durable responses will require moving beyond single-agent therapy toward rational combination regimens. Preclinical and clinical evidence across malignancies supports combining kinase inhibitors with immune checkpoint blockade. In non-small cell lung cancer, the JAK1 inhibitor itacitinib combined with pembrolizumab achieved a 12-week overall response rate of 62 percent with a median progression-free survival of 23.8 months. In Hodgkin lymphoma, ruxolitinib combined with nivolumab yielded an overall response rate of 53 percent, with ruxolitinib appearing to rescue exhausted T cells and synergize with checkpoint blockade in reshaping the myeloid compartment. Although no clinical trials have yet evaluated such combinations in aggressive T-cell lymphomas, the authors suggest these approaches warrant investigation given the immune-evasive nature of these tumors. Topical application of inhibitors might also circumvent systemic toxicity and provide a window for prolonged therapeutic efficacy.

Aggressive cutaneous T-cell lymphoma thus presents both a challenge and an opportunity for precision dermato-oncology. The discovery of recurrent kinase alterations reveals that subsets of these lymphomas are mechanistically dependent on constitutive kinase activity for survival and proliferation, making them vulnerable to targeted inhibition. Yet the predictable emergence of adaptive resistance—through gatekeeper mutations, cooperative cross-kinase substitutions, and toxicity-driven dose reductions—underscores that single-agent approaches are insufficient. Future progress, the authors conclude, relies on molecular stratification based on kinase dependency, longitudinal genomic monitoring to detect resistance as it emerges, rational combination therapy, and the development of mutation-selective next-generation inhibitors capable of overcoming the adaptive mechanisms that currently limit treatment durability.

Subject of Research: Kinase inhibitor resistance in cutaneous T-cell lymphomas

Article Title: Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

Article References: Yescas, J. A., Bunick, C. G., Grada, A., Guitart, J., Torres-Cabala, C. A., Le Poole, I. C., & Zhou, X. A. (2026). Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas. Frontiers in Hematology, 5, Article 1812908. https://doi.org/10.3389/frhem.2026.1812908

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1812908

Keywords: cutaneous T-cell lymphoma, kinase inhibitors, drug resistance, JAK/STAT pathway, FGFR1, precision oncology, hematology, Mechanisms, kinase, inhibitor, resistance, subtypes

The challenge that motivated the work is well known to cardio-oncologists. When a patient receiving checkpoint inhibitors develops chest pain, arrhythmias, or rising cardiac troponin levels, clinicians must distinguish true ICI-myocarditis from other causes of cardiac stress in a cancer population. Current diagnosis relies heavily on biomarkers, electrocardiography, cardiac magnetic resonance imaging, and, in severe cases, endomyocardial biopsy, which is invasive and rarely performed early. Without a clear molecular understanding of what the immune system is actually doing during the attack on heart muscle, the field has lacked both precise diagnostics and rational targeted therapies. The Shanghai group set out to close that gap by examining immune cells directly, at single-cell resolution, in patients before and after the onset of disease.

Using single-cell RNA sequencing of peripheral blood mononuclear cells, the researchers profiled the circulating immune compartment of patients with ICI-myocarditis and compared it with that of cancer patients receiving checkpoint inhibitors who remained free of cardiac toxicity. The analysis revealed a striking expansion of a subset of CD8-positive T cells expressing ISG15, a protein induced by type I interferon signaling. These ISG15-positive CD8 T cells carried a strongly proinflammatory transcriptional program, suggesting they were not passive bystanders but active participants in the autoimmune assault on the myocardium. The finding was consistent across patients and was corroborated by independent flow cytometry measurements of the same cell populations.

Crucially, the ISG15-positive T cells did not appear to act alone. The single-cell data showed that their abundance at baseline correlated with proinflammatory features in monocytes, the innate immune cells that can amplify tissue damage through cytokine release and antigen presentation. Computational analysis of ligand-receptor interactions across cell types suggested that the communication between these two compartments may be mediated, at least in part, by the CCL2-CCR2 chemokine axis, a well-characterized signaling pathway that recruits monocytes expressing the CCR2 receptor toward sites of inflammation. In other words, the T cells appeared to summon and activate the monocytes, creating a self-reinforcing inflammatory loop in the heart.

To test whether these circulating cells were genuinely cardiotoxic rather than merely correlated with disease, the team performed in vitro experiments. They isolated the ISG15-positive CD8 T cells from patient blood and co-cultured them with cardiomyocytes, observing that these cells showed a high potential to induce apoptosis, or programmed cell death, in the heart muscle cells. This functional evidence supports the pathogenic role that the transcriptional data had implied: the very cells enriched in patients who develop myocarditis carry the molecular machinery to kill cardiomyocytes. It is a direct demonstration, at the cellular level, of how checkpoint inhibitor therapy can tip the immune system toward self-destruction of cardiac tissue.

The translational payoff of the study comes in two forms. The first is diagnostic. Based on the inflammatory signature identified in the multi-omics data, the researchers developed a custom panel of eight proteins measurable in blood, selected from the proteomic and cytokine profiles that distinguished ICI-myocarditis patients from other checkpoint inhibitor-treated controls. The panel showed promising performance in separating true myocarditis from patients on the same drugs who did not develop cardiac toxicity. If validated in larger, prospective cohorts, such a panel could allow oncologists and cardiologists to identify or rule out ICI-myocarditis earlier and with greater confidence than current biomarkers alone, potentially preventing the delays that contribute to the condition’s high fatality rate.

The second payoff is therapeutic. The integrated analysis pointed to JAK-STAT signaling, a central intracellular pathway downstream of many inflammatory cytokine receptors, as a shared driver of the inflammatory programs in both the ISG15-positive CD8 T cells and the activated monocytes. In mouse models of ICI-induced cardiac injury, pharmacological inhibition of the JAK-STAT pathway ameliorated cardiac dysfunction and reduced inflammatory infiltration into the heart. Remarkably, the intervention did not simply blunt the autoimmune attack; it also enhanced the response to anti-PD-1 therapy in the same models. That dual effect is significant because the ideal treatment for ICI-myocarditis would suppress the cardiac toxicity without sacrificing the anti-tumor benefit that motivated checkpoint blockade in the first place.

The chemokine axis offered a parallel therapeutic target. When the researchers blocked the CCL2-CCR2 axis in vivo, the intervention attenuated ICI-induced cardiac injury in the animal models, consistent with the idea that disrupting the recruitment of CCR2-expressing monocytes can break the inflammatory loop that damages the myocardium. Together, the JAK-STAT and CCL2-CCR2 findings suggest that ICI-myocarditis is not an undifferentiated inflammatory storm but a structured pathological circuit with defined nodes that can be pharmacologically intercepted. Each node represents a potential drug target, and several JAK inhibitors and CCR2 antagonists already exist in the clinical pharmacology arsenal for other inflammatory diseases, which could accelerate the path to clinical testing.

The study also carries implications for risk prediction before therapy begins. The observation that high levels of baseline ISG15-positive CD8 T cells are linked to the development of myocarditis raises the possibility of screening patients before they start checkpoint inhibitors, identifying those whose immune systems are already primed for interferon-driven, cytotoxic anti-cardiac responses. Such pre-treatment stratification remains speculative until prospective studies confirm the predictive value of the signature, but it fits a broader trend in immuno-oncology toward tailoring therapy to a patient’s baseline immune state rather than reacting to toxicity after it appears.

Cautions remain. The human findings rest on peripheral blood measurements, which serve as a window into the immune response but do not fully capture the inflammatory milieu inside the heart muscle itself, where tissue-resident immune populations may behave differently. The mouse models, while supportive, recapitulate only parts of the human disease. And the eight-protein diagnostic panel, however promising, will need rigorous external validation across diverse cancer types, treatment regimens, and ethnic populations before it can enter routine clinical use. Nevertheless, by integrating single-cell transcriptomics, proteomics, cytokine profiling, and functional experiments into a single coherent picture, the Zhongshan Hospital team has converted a poorly understood, frequently fatal complication into a molecularly defined disease with identifiable cellular culprits, a candidate blood-based diagnostic, and two mechanistically grounded therapeutic strategies. For the growing population of patients whose cancers are treated with checkpoint inhibitors, that transformation is a meaningful step toward making immunotherapy’s most dangerous side effect predictable, detectable, and treatable.

Subject of Research: Immune mechanisms, diagnosis, and treatment of immune checkpoint inhibitor-induced myocarditis

Article Title: Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis

Article References: Zhang, S.-L., Cai, Q.-Q., Zhang, J., Liu, Y., Lu, H., Zhang, Y.-R., Xu, Y.-C., Peng, H.-X., Chen, H.-Y., Wang, Y., Cheng, L.-L., & Ge, J.-B. (2026). Integrated multi-omics identifies distinct immune signatures with diagnostic and therapeutic implications in immune checkpoint inhibitor-induced myocarditis. Nature Communications. https://doi.org/10.1038/s41467-026-77262-0

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77262-0

Keywords: immune checkpoint inhibitors, myocarditis, CD8 T cells, ISG15, monocytes, CCL2-CCR2 axis, JAK-STAT pathway, single-cell RNA sequencing, proteomics, cardiotoxicity, cancer immunotherapy, biomarkers

The stakes are considerable. Osteoarthritis affects an estimated 7 to 8 percent of the global population, while rheumatoid arthritis invades roughly 0.2 to 1 percent of people worldwide. Both conditions become more prevalent with age, and researchers increasingly view aging itself as an underlying hallmark of arthritis progression. As life expectancy rises and the aged population grows exponentially across the globe, the search for therapies that can protect aging joints has become a central concern of biomedical research, a field known as geroprotection.

Current treatment options leave much to be desired. Non-steroidal anti-inflammatory drugs, the mainstay of symptomatic relief, are widely regarded as a secondary treatment option because of their high cost, inadequate pharmacological action in many patients, and well-documented adverse effects ranging from gastrointestinal bleeding to kidney damage. There is no cure for either osteoarthritis or rheumatoid arthritis, and despite decades of research into their pathogenesis, efficient curable approaches remain challenging. This therapeutic gap has driven a demographic shift toward polyherbal medicines, particularly formulations designed to inhibit pro-inflammatory cytokines, the signaling molecules that drive joint destruction.

Triphalaguggul is precisely such a formulation. Triphala, a balanced combination of the fruits of three plants, has long been used in Indian systems of medicine as a rejuvenating tonic, and prior studies have shown that Triphala herbal extract can suppress inflammatory responses in macrophages and in arthritic rats by inhibiting the NF-κB pathway. Guggul, the resin of Commiphora wightii, contributes guggulsterones and other phytochemicals with documented anti-inflammatory properties. The research team hypothesized that combining these ingredients would target the downregulation of pro-inflammatory cytokines and their signaling pathways, addressing the molecular engine of arthritis rather than merely its symptoms.

To test this, the researchers ran two complementary disease models in rats. Osteoarthritis was induced by intra-articular injection of monosodium iodoacetate, a compound that selectively kills chondrocytes, the cartilage-producing cells of the joint, and thereby mimics the progressive cartilage degradation seen in human osteoarthritis. Rheumatoid arthritis was modeled using complete Freund’s adjuvant, an immunological challenge that triggers chronic, systemic joint inflammation resembling the autoimmune attack characteristic of rheumatoid arthritis. Alongside these efficacy studies, the team conducted toxicological evaluations to establish the safety profile of the formulation.

The results were dramatic. In the osteoarthritis model, Triphalaguggul reduced inflamed knee measurements by 96.15 percent and paw edema by 95.18 percent. Perhaps more importantly, histological examination showed that the treatment helped chondrocytes regrow and rearrange themselves properly within the damaged cartilage, suggesting genuine structural repair rather than simple suppression of swelling. In the rheumatoid arthritis model, blood chemistry markers that typically spike during active disease were brought back into line. Elevated levels of the liver enzymes SGPT and SGOT, alkaline phosphatase, C-reactive protein, and rheumatoid factor were all reinstated to their normal ranges after treatment, with statistical significance at p < 0.05.

The molecular story behind these outcomes centers on three cytokines: interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta. These pro-inflammatory messengers are central to the pathology of both joint diseases. In osteoarthritis, they drive the catabolic cascade that degrades cartilage matrix; in rheumatoid arthritis, they orchestrate the autoimmune inflammation that erodes bone and synovium. Using enzyme-linked immunosorbent assays, the team showed that levels of all three cytokines, which had risen sharply in the arthritic animals, fell significantly after Triphalaguggul treatment.

Downstream of these cytokines lie two of the most important signaling highways in inflammation biology: the JAK/STAT pathway and the NF-κB pathway. When interleukin-6 or related cytokines bind their receptors, they activate Janus kinase 2, which in turn phosphorylates the transcription factor STAT3, sending it into the nucleus to switch on inflammatory genes. In parallel, the p65 subunit of nuclear factor kappa B translocates to the nucleus to activate another battery of inflammatory genes, including those encoding cytokines themselves, creating a self-amplifying loop. The researchers found that the enhanced expression of phosphorylated JAK2, phosphorylated STAT3, and NF-κB p65 seen in arthritic rats was significantly downregulated after treatment. These findings were validated by two independent techniques, western blotting, which quantifies protein abundance, and immunohistochemistry, which maps protein localization within tissue sections, lending robustness to the conclusion.

By demonstrating that a single polyherbal formulation can simultaneously quiet cytokine production and dampen both major inflammatory signaling cascades, the study positions Triphalaguggul as a candidate geroprotective therapy, one that targets pro-inflammatory cytokines and the JAK/STAT and NF-κB pathways as therapeutic biomarkers of aging-related joint disease. The framing matters: rather than treating osteoarthritis and rheumatoid arthritis as separate problems, the work treats chronic low-grade inflammation as a shared molecular thread running through aging and arthritis alike, and proposes that pulling that thread with a well-characterized herbal mixture could protect against geriatric disease more broadly.

Substantial caveats remain before this ancient formula reaches modern pharmacies. The evidence comes entirely from chemically induced rat models, which reproduce key features of human joint disease but do not capture its full complexity, and dose translation between laboratory animals and humans is a well-known hurdle in preclinical drug development. Human clinical trials, standardization of the formulation, and pharmacokinetic characterization of its active constituents will all be required. Still, the study adds rigorous molecular data to a growing body of literature on traditional herbal medicines, from curcumin to guggulsterones, that modulate exactly the inflammatory pathways targeted by modern biologics. For the millions of people whose aging joints ache with inflammation, the possibility that a validated, affordable, and safe botanical alternative could emerge from a millennium-old prescription is a prospect worth watching closely.

Subject of Research: Anti-arthritic and geroprotective effects of the polyherbal formulation Triphalaguggul on cytokine signaling in rat models of osteoarthritis and rheumatoid arthritis

Article Title: Geroprotective efficacy of Triphalaguggul: a polyherbal formulation against inflammatory disorders through inhibition of pro-inflammatory cytokines as therapeutic biomarkers

Article References: Dey, A., Datta, S., Gupta, M., Chattapadhyay, H., & Sahoo, P. K. (2026). Geroprotective efficacy of Triphalaguggul: a polyherbal formulation against inflammatory disorders through inhibition of pro-inflammatory cytokines as therapeutic biomarkers. Biogerontology, 27(5), Article 176. https://doi.org/10.1007/s10522-026-10519-9

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10519-9

Keywords: Triphalaguggul, osteoarthritis, rheumatoid arthritis, pro-inflammatory cytokines, JAK/STAT pathway, NF-κB, Ayurveda, guggul, Triphala, geroprotection, rat models, IL-6

The research team recruited three carefully matched groups of twenty participants each: adolescents diagnosed with depression but no history of self-injury, adolescents with depression who engaged in non-suicidal self-injury, and mentally healthy controls. Each participant provided a blood sample, and the researchers measured the levels of dozens of circulating proteins using the Olink proximity extension assay, a technology that pairs antibodies with DNA tags so that minute quantities of proteins can be quantified with high specificity from small plasma volumes. This approach allowed the team to scan the peripheral immune landscape without relying on invasive procedures such as lumbar puncture.

The first comparison established a baseline: depression alone, relative to healthy controls, was associated with eleven differentially expressed proteins. Among the most striking changes were significant elevations of IL-17A, IL-10, and CCL19, alongside reductions in IL-13 and CCL11. These proteins span the classical cytokine axis, including pro-inflammatory interleukins, regulatory anti-inflammatory signals, and chemokines that orchestrate immune cell trafficking. When the researchers ran pathway enrichment analyses on this set, the proteins clustered strongly in inflammatory response, cytokine-mediated signaling, immune response, and cytokine activity, reinforcing the long-standing hypothesis that adolescent depression involves measurable peripheral inflammation rather than being purely a disorder of mood and cognition.

The more revealing comparison, however, came from contrasting the two depressed groups against each other. Adolescents with depression and comorbid self-injury showed seven proteins that differed significantly from their depressed but non-self-injuring peers. Five were elevated: matrix metalloproteinase-1, oncostatin M, hepatocyte growth factor, vascular endothelial growth factor A, and caspase-8. Two were reduced: cystatin D and CD6. This pattern is biologically coherent. MMP-1 is an enzyme that degrades extracellular matrix components and is often upregulated during tissue remodeling under inflammatory stress. Oncostatin M is an inflammatory cytokine in the interleukin-6 family with well-documented effects on neuroinflammation and the blood-brain barrier. HGF and VEGFA are growth factors involved in vascular repair and permeability, while caspase-8 sits at the gateway of apoptotic and inflammatory cell-death pathways. Cystatin D and CD6, by contrast, are linked to protease inhibition and immune regulation respectively, and their reduction hints at a loss of counterbalancing control.

Pathway analysis of these seven proteins pointed to specific signaling circuits. Using the Kyoto Encyclopedia of Genes and Genomes framework, the team found significant enrichment in TNF signaling, IL-17 signaling, and JAK-STAT signaling. All three pathways are central conduits through which peripheral immune activation can communicate with the central nervous system. TNF and IL-17 signaling are hallmarks of chronic inflammation and have been implicated in stress-induced changes in brain circuits governing emotion and impulse control. The JAK-STAT pathway translates cytokine signals arriving at cell membranes into changes in gene expression, meaning that sustained elevation of oncostatin M or related cytokines could, in principle, reprogram stress-responsive neurons and glial cells. Because the blood-brain barrier becomes more permeable under inflammatory conditions, and because VEGFA and HGF themselves regulate vascular permeability, the authors suggest these proteins may represent a peripheral window into inflammatory crosstalk affecting the brain.

Perhaps the most clinically tantalizing result emerged when the researchers tested whether the protein signatures could distinguish self-injuring adolescents from depressed adolescents without self-injury. A panel combining all seven differentially expressed proteins achieved an area under the receiver operating characteristic curve of 0.825, a level of discrimination that, if replicated, could support the development of a blood-based screening tool. A leaner four-protein panel consisting of CD6, cystatin D, VEGFA, and HGF performed nearly as well, with an area under the curve of 0.800. In a field where risk assessment currently depends almost entirely on clinical interviews and self-report questionnaires, a measurable biomarker panel would represent a meaningful shift toward objective risk stratification.

The team went further by connecting protein levels to the fine-grained structure of self-injurious behavior. Using validated NSSI scales that break the behavior into specific actions, motivations, and frequencies, they computed correlations between each protein and individual scale items. MMP-1, oncostatin M, and VEGFA levels correlated positively with several behavioral indices, including items measuring the frequency and form of self-injury. MMP-1 in particular tracked motivational dimensions of the behavior, correlating with items assessing why adolescents engage in self-harm, while oncostatin M and VEGFA tracked the behavioral items themselves. Linear regression analysis confirmed that these associations held after accounting for other variables, suggesting the protein signals are not merely proxies for overall depression severity but are specifically tied to the self-injury phenotype.

Statistical rigor was a feature of the analysis throughout. The researchers applied Benjamini-Hochberg correction to control the false discovery rate across the many protein comparisons, and they used both Pearson and Mantel tests to verify the correlations between protein levels and behavioral scores. The study also received ethics approval from two independent hospital committees and was conducted under the Declaration of Helsinki, with written informed consent obtained from every participant or their legal guardian. These methodological safeguards matter because small-sample proteomic studies are vulnerable to spurious findings, and the field of psychiatric biomarkers has been repeatedly criticized for underpowered and unreplicated claims.

That caveat leads directly to the study’s principal limitation, which the authors state plainly: the findings require independent validation before any clinical use. With twenty participants per group, the results should be regarded as hypothesis-generating rather than definitive. Self-injury in adolescents is influenced by a web of psychological, social, and familial factors, and no single protein panel will capture that complexity. Moreover, the cross-sectional design cannot determine whether the observed protein changes precede the onset of self-injury, result from it, or reflect a shared upstream cause such as chronic stress. Longitudinal studies following at-risk adolescents over time, and replication in larger and more diverse cohorts, will be essential next steps.

Even with those qualifications, the study adds a significant piece to a rapidly growing body of work linking immune dysregulation to self-directed harm. It moves the conversation beyond the question of whether inflammation matters in adolescent depression toward the more precise question of which inflammatory pathways distinguish the subgroup of depressed adolescents at highest risk of hurting themselves. If the seven-protein signature, or the leaner four-protein version, survives validation, clinicians could one day pair a simple blood draw with existing psychological assessments to identify vulnerable patients earlier, intervene sooner, and potentially prevent the escalation of self-injurious behavior during one of the most treatable windows of psychiatric development. For now, the study stands as a compelling demonstration that the biology of self-harm leaves traces in the blood that modern proteomics can finally read.

Subject of Research: Immuno-inflammatory plasma protein changes associated with non-suicidal self-injury in adolescents with depression

Article Title: Olink proteomics reveals immuno-inflammatory profile changes and potential regulatory mechanisms of non-suicidal self-injury behavior associated with depression in adolescent

Article References: Xu, H., Liang, X., Xia, Y., Fang, X.-L., Xu, C.-H., Wu, P.-P., Wang, D.-C., Song, C.-F., & Yang, F. (2026). Olink proteomics reveals immuno-inflammatory profile changes and potential regulatory mechanisms of non-suicidal self-injury behavior associated with depression in adolescent. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08624-7

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08624-7

Keywords: adolescent depression, non-suicidal self-injury, Olink proteomics, biomarkers, TNF signaling, IL-17 signaling, JAK-STAT pathway, MMP-1, VEGFA, oncostatin M, inflammation, BMC Psychiatry

The central thesis of the review is that the EGFR–STAT3 axis should not be understood as a simple linear pathway in which a signal travels from receptor to nucleus. Instead, the authors propose that it functions as an adaptive resistance hub, a dynamic network node that integrates inputs from growth factor signaling, inflammatory cytokines, hypoxic stress, tumor-associated macrophages, and the pharmacological pressure exerted by therapy itself. When EGFR is pharmacologically inhibited, the signal transducer and activator of transcription 3, or STAT3, can remain persistently active through alternative routes, sustaining the oncogenic transcriptional programs that EGFR blockade was supposed to shut down. This compensatory activation, the review argues, is the mechanistic heart of adaptive resistance in glioblastoma, and it explains why single-agent EGFR therapies have repeatedly come up short.

To appreciate the significance of this argument, it helps to understand the molecular mechanics involved. Under normal conditions, EGFR activation at the cell membrane triggers a cascade that includes the JAK kinases, which phosphorylate STAT3, allowing it to dimerize, translocate to the nucleus, and switch on genes that promote proliferation, survival, and invasion. In many cancers, this canonical route is the dominant driver of STAT3 activity. But glioblastoma is not an ordinary cancer. The tumor microenvironment of the brain is saturated with alternative activators of STAT3 that operate entirely independently of EGFR. Interleukin-6 and other inflammatory cytokines released by tumor-associated macrophages and microglia can activate the JAK/STAT3 pathway directly. Hypoxia, a hallmark of the glioblastoma microenvironment, has been shown to drive STAT3-mediated self-renewal of glioma stem-like cells through secretion-mediated signaling. The result is a tumor in which STAT3 remains lit even when the receptor at the top of the pathway has been chemically silenced.

This non-canonical, microenvironment-driven STAT3 activation has profound consequences for every pillar of current glioblastoma therapy. The review systematically lays out how persistent STAT3 signaling promotes glioma stemness, the maintenance of a self-renewing population of tumor-initiating cells that are notoriously resistant to both chemotherapy and radiotherapy. It also describes how STAT3 drives metabolic reprogramming, allowing tumor cells to adapt their energy metabolism to the nutrient-poor, oxygen-starved conditions of the tumor core. Perhaps most strikingly, STAT3 activity shapes the immune landscape of the tumor, fostering immune suppression and immune evasion that undermine both endogenous antitumor immunity and emerging immunotherapeutic approaches. In other words, STAT3 is not merely a backup signal; it is a master regulator of the resistant state that glioblastoma adopts under therapeutic pressure.

The clinical record bears out this mechanistic picture. The review recounts a series of high-profile failures in EGFR-directed therapy for glioblastoma, including trials of tyrosine kinase inhibitors such as erlotinib and osimertinib, the EGFR-targeted antibody-drug conjugate depatuxizumab mafodotin in EGFR-amplified newly diagnosed disease, and the EGFRvIII vaccine rindopepimut in relapsed tumors expressing that mutation. In each case, the molecular rationale was sound, and in each case the tumor found a way around the blockade. Recent work cited in the review has shown that resistance to EGFR antibody-drug conjugates is driven by transcriptional reprogramming and TEK-induced EGFR suppression, further illustrating that the tumor’s escape routes extend beyond simple pathway reactivation. What unites these observations is the emerging consensus that compensatory signaling, with STAT3 as a critical node, allows glioblastoma to survive targeted attack.

Importantly, the review does not treat this as a purely glioblastoma-specific problem. The authors draw on evidence from other cancers, including lung and colorectal tumors, where feedback activation of STAT3 has been documented as a general drug-resistance mechanism following EGFR inhibition. Clinical trials in EGFR-mutant lung cancer have tested combinations of EGFR inhibitors with JAK inhibitors such as ruxolitinib and momelotinib, providing proof of concept that dual blockade of the axis is feasible in patients. This cross-cancer perspective strengthens the argument that the EGFR–STAT3 crosstalk is a fundamental property of oncogene-addicted tumors rather than an idiosyncrasy of brain cancer, and it suggests that lessons learned in other tumor types could be translated to glioblastoma, provided the unique challenges of the blood–brain barrier are addressed.

That barrier is one of the practical obstacles the review confronts head-on. Delivering signaling inhibitors to the brain remains notoriously difficult, and the authors discuss drug-delivery innovations designed to overcome it, including sustained-release hydrogel systems engineered to deliver the JAK inhibitor ruxolitinib directly to glioma tissue. Preclinical studies have shown that ruxolitinib can enhance the cytotoxic and apoptotic effects of temozolomide on glioblastoma cells, and that EGFR blockade in glioblastoma brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate the compensatory mechanisms that otherwise allow the stem-cell compartment to survive. These findings point toward a therapeutic logic of vertical and horizontal pathway suppression: hitting EGFR and STAT3 simultaneously, rather than sequentially, so that the tumor has no intact escape route left to exploit.

The review also surveys a broader arsenal of strategies aimed at the axis. Dual-target inhibitors that engage both EGFR and JAK3 have been developed and shown to overcome resistance driven by KRAS mutations in colorectal cancer, offering a template for similar agents in glioblastoma. Natural-product-derived compounds, including resveratrol, have been reported to enhance temozolomide efficacy by downregulating MGMT and inactivating STAT3 through its negative regulators, and to ameliorate the inflammatory tumor response by suppressing NLRP3 inflammasome activation via the JAK2/STAT3 pathway. Pyrimidine compounds such as BY4003 and BY4008 have been shown to inhibit glioblastoma cell growth by modulating JAK3/STAT3 signaling. Exosome-based approaches, including circPRKD3-loaded extracellular vesicles that inhibit STAT3 signaling while simultaneously remodeling the tumor microenvironment, represent a nanoscale delivery strategy that targets both the tumor cells and their supporting stroma. Each of these approaches attacks a different face of the same adaptive hub.

The immunological dimension of STAT3 inhibition deserves particular emphasis, because it may determine whether the next generation of glioblastoma therapy succeeds where checkpoint blockade has failed. STAT3 is a central regulator of the immunosuppressive glioblastoma microenvironment, shaping the behavior of tumor-associated macrophages, microglia, and regulatory T cells. Preclinical work has shown that combining radiation with STAT3 blockade triggers dendritic cell–T cell interactions in the glioma microenvironment and improves therapeutic efficacy, suggesting that STAT3 inhibition could convert a immunologically cold tumor into one that responds to immunotherapy. Given the disappointing results of anti-PD-1 and anti-PD-L1 agents as monotherapy in glioblastoma, the prospect of using axis-targeted therapy to prime the immune system represents one of the most compelling rationales for pursuing this strategy in the clinic.

What emerges from this comprehensive synthesis is a reframing of the glioblastoma problem. The tumor is not simply an EGFR-driven cancer that has eluded EGFR drugs; it is an adaptively resistant ecosystem in which the EGFR–STAT3 axis functions as the integrating hub of survival under stress. The authors’ systematic dissection of the molecular mechanisms underlying EGFR–STAT3 crosstalk, their attention to non-canonical and microenvironment-driven STAT3 activation, and their honest accounting of past therapeutic failures together build a case that future trials must be designed around combination strategies that close the escape routes before they open. No clinical data yet confirm that dual EGFR–STAT3 blockade will improve outcomes for glioblastoma patients, and the review is careful to frame its conclusions as a proposal grounded in accumulating evidence rather than a proven treatment paradigm. But the logic is clear and the preclinical foundation is strengthening: to break adaptive oncogenic resistance in one of medicine’s most lethal cancers, the field may need to stop attacking single nodes and start disabling the entire rewired network at once.

Subject of Research: Adaptive resistance mechanisms mediated by the EGFR–STAT3 signaling axis in glioblastoma

Article Title: Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR–STAT3 axis

Article References: Ahmad, N., & Ullah, A. (2026). Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR–STAT3 axis. Medical Oncology, 43(11), Article 327. https://doi.org/10.1007/s12032-026-03459-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03459-4

Keywords: glioblastoma, EGFR, STAT3, JAK/STAT pathway, adaptive resistance, targeted therapy, tumor microenvironment, glioma stem cells, immunosuppression, temozolomide, drug resistance, brain tumor

The retraction notice, published in the same journal, explains that after publication, concerns were raised regarding image irregularities. When the authors were contacted to clarify the issues, they did not respond. In the world of research integrity, that silence is often decisive. Journals typically give authors an opportunity to explain anomalies in their figures, and when those explanations fail to materialize, editors are left with little choice but to retract. The notice is unambiguous: the editors no longer trust the findings, and the scientific record has been corrected accordingly.

The specific concerns are technical but instructive. According to the retraction notice, a panel in Figure 3B of the retracted paper, labeled as an IL-1 beta condition at a concentration of 10 nanograms per milliliter, appears to overlap with a panel in Figure 6C of a separate 2019 article on nasopharyngeal carcinoma published in Cancer Cell International. Strikingly, the same panel also appears to overlap with a panel in Figure 2D of a second, unrelated paper on pancreatic cancer that has itself since been retracted. In plain terms, identical or nearly identical images seem to have been used to represent entirely different experiments in entirely different disease contexts, spanning osteoarthritis, nasopharyngeal cancer, and pancreatic cancer.

This kind of image duplication is one of the most common triggers for retractions in the modern era of research integrity screening. Western blots, microscopy fields, and other gel-based or imaging outputs are supposed to be unique records of individual experiments. When the same image shows up in multiple papers, or in multiple figures within a single paper, it suggests either careless figure assembly or deliberate fabrication. Software tools and vigilant readers now routinely flag such overlaps, and journals have invested heavily in automated screening pipelines that compare figures across vast swaths of the published literature. What once might have slipped through unnoticed for decades can now be detected within months or years of publication.

The retraction also contains a second, more troubling element: a disputed authorship claim. One of the listed authors, Zhiguang Qiao, stated that he did not contribute to the study and did not consent to being listed as an author of the article. The remaining authors, according to the notice, have not responded to correspondence regarding the retraction. Authorship disputes of this kind raise questions that go beyond the integrity of the data itself. Authorship carries professional credit, responsibility, and accountability, and being listed on a paper without consent is a serious matter. Conversely, when a paper is retracted, every listed author shares in the reputational damage, which is precisely why consent and genuine contribution matter so much.

The original study, published on 7 October 2019, had explored a question of real clinical interest. Osteoarthritis is the most common form of arthritis, affecting hundreds of millions of people worldwide, and its hallmark is the slow degeneration of joint cartilage accompanied by chronic inflammation. Current treatments largely manage symptoms with painkillers and anti-inflammatory drugs, but nothing on the market halts or reverses the underlying disease. That gap has fueled intense interest in natural compounds with anti-inflammatory properties, and acteoside has been one of the candidates. Found in plants such as those used in traditional medicine systems, acteoside had been reported in various laboratory studies to modulate inflammatory signaling, and the JAK/STAT pathway, a chain of molecular interactions that transmits signals from the cell surface to the nucleus, is a well-established regulator of immune and inflammatory responses. Drugs targeting this pathway are already approved for conditions including rheumatoid arthritis, so the hypothesis that a plant compound might act similarly in osteoarthritis was scientifically plausible.

Plausible, however, is not the same as demonstrated. The retraction does not merely erase a single data point; it removes the evidentiary basis for the paper’s central claim that acteoside inhibits inflammatory responses via JAK/STAT signaling in osteoarthritic rats. Readers who encounter the paper in databases or citation lists will now find it flagged as retracted, and responsible researchers will exclude it from systematic reviews and meta-analyses. This matters because complementary and alternative medicine research is frequently cited in public discussions of herbal remedies, and retracted findings can linger in the popular imagination long after the formal correction. A retraction notice is a small document, but its function is to stop the spread of unreliable conclusions before they harden into accepted wisdom.

The case also illustrates the interconnected nature of research integrity problems. The two articles whose figures allegedly overlap with the retracted osteoarthritis paper are themselves notable: one, on circular RNA in nasopharyngeal carcinoma, remains in the literature as far as the notice indicates, while the other, a study of solasodine against pancreatic cancer, is explicitly labeled as retracted. When the same images surface across papers from what appear to be different research groups or different disease areas, integrity investigators often look for common threads, such as shared figure-preparation services, paper mills, or overlapping authorship networks. The retraction notice itself does not draw such conclusions, and it would be wrong to speculate beyond what the editors have stated. But the pattern of a single panel appearing in three different disease contexts is exactly the kind of red flag that has, in other cases, led to much larger sweeps of retractions.

For the journal, BMC Complementary Medicine and Therapies, the retraction is part of a broader reckoning. Journals in the complementary medicine space have faced particular scrutiny in recent years, in part because the field attracts a high volume of submissions and in part because several journals in adjacent areas experienced mass retractions linked to paper mills. Editors have responded with stricter checks at submission, including image forensics, statistical scrutiny, and requirements for raw data. The fact that this retraction was issued years after the original publication, and that the notice was published in 2026 with a new article number and DOI, reflects the often slow but methodical pace of post-publication correction. Investigations take time, correspondence with authors can drag on for months, and legal considerations sometimes complicate matters further.

What should readers take away from this episode? First, that the self-correcting machinery of science, however slow, does function. A paper published in 2019 has been formally retracted, its problems documented, and its authors given the chance to respond. Second, that images are evidence. The figures in a scientific paper are not illustrations; they are the data themselves, and their integrity is inseparable from the integrity of the conclusions. Third, that authorship is a responsibility, not just a credit line, and disputes about who did or did not contribute are treated with seriousness by editors. And finally, that single studies, especially early animal studies of natural compounds, should always be viewed as provisional. The hypothesis that acteoside might calm inflammation in arthritic joints may yet be tested rigorously by other groups with clean data. Until then, the scientific record now accurately reflects what is and is not known, and that accuracy is the foundation on which all future research depends.

Subject of Research: Retraction of a study on acteoside and the JAK/STAT inflammatory pathway in osteoarthritis due to image irregularities

Article Title: Retraction Note: Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats

Article References: Qiao, Z., Tang, J., Wu, W., Tang, J., & Liu, M. (2026). Retraction Note: Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats. BMC Complementary Medicine and Therapies, 26(1), Article 285. https://doi.org/10.1186/s12906-026-05627-5

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05627-5

Keywords: retraction, acteoside, osteoarthritis, JAK/STAT pathway, research integrity, image duplication, BMC Complementary Medicine and Therapies, authorship dispute, inflammation, natural compounds, scientific publishing, figure manipulation